phrykt

Cingulate Inc. (CING): who owns it and who trades it

As of Nov 16, 2026, CING insiders reported 5 purchases worth $657K in the last 12 months. The largest buyer was Thomas Jeffrey Hargroves (Director), with $490K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Cingulate

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, CING insiders reported $657K of open-market purchases and $0 of sales.

Purchases, 12 months
$657K
5 trades, 5 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Feb 13, 2026
Filed Jun 8, 2026

Purchases and sales by month

$657K$657KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Feb 13, 2026Thomas Jeffrey HargrovesDirectorPurchase97,276$5.04$490KForm 4
Feb 6, 2026Peter J. WerthDirectorPurchase19,455$5.04$98.1KForm 4
Feb 6, 2026Jennifer L. CallahanCFOPurchase4,864$5.04$24.5KForm 4
Feb 6, 2026Shane J. SchafferCEOPurchase6,809$5.04$34.3KForm 4
Feb 6, 2026Matthew BramsVice presidentPurchase1,946$5.04$9.8KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Thomas Jeffrey HargrovesDirector$490K–Feb 13, 2026
Peter J. WerthDirector$98.1K–Feb 6, 2026
Shane J. SchafferChief Executive Officer, Director$34.3K–Feb 6, 2026
Jennifer L. CallahanSVP and CFO$24.5K–Feb 6, 2026
Matthew BramsEVP and Chief Medical Officer$9.8K–Feb 6, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CING short interest

Moderate short interest. 7.1% of CING shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went down 34%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.04M CING shares were sold short, 7.1% of the shares outstanding, up 2.0% from the report before. At the average daily volume of 138,009 shares, buying them all back would take about 7.5 trading days (days to cover).

Shares short, % of all shares

7.14%May 15Oct 3018.3%

Days to cover

7.5May 15Oct 3015.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.04M7.14%+2%138,0097.5
Oct 15, 20261.02M6.99%-1%86,17411.8
Sep 30, 20261.03M7.09%-12%98,27810.5
Sep 15, 20261.17M8.05%+11%86,54813.5
Aug 31, 20261.06M7.26%-12%161,2006.5
Aug 14, 20261.20M8.27%-23%154,2527.8
Jul 31, 20261.57M13.50%-6%156,73410.0
Jul 15, 20261.68M14.43%+22%348,8264.8
Jun 30, 20261.38M11.83%-22%381,6383.6
Jun 15, 20261.76M15.15%-10%923,1941.9
May 29, 20261.96M16.85%+24%639,7443.1
May 15, 20261.58M13.56%+5%442,5573.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Cingulate company events

Cingulate filed 19 reports on Form 8-K in the last 12 months, 8 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026AnnouncementIn October 2025, we announced that the FDA accepted for review our NDA for CTx-1301 and assigned a Prescription Drug User Fee Act (PDUFA) targeted action date of May 31, 2026. Filing
  2. Oct 2, 2026LeadershipCingulate Therapeutics LLC, a wholly owned subsidiary of Cingulate Inc., entered into amendment No. 2 to the Employment Agreement between Matthew N. Brams, Executive Vice President and Chief Medical Officer, and CTx, effective January 1, 2026. Filing
  3. Aug 13, 2026ResultsReleased financial results. Filing
  4. Jul 23, 2026LeadershipThe Board of Directors of Cingulate Inc. determined to eliminate the Chief Legal Officer position. Filing
  5. Jul 14, 2026LeadershipEquity Plan Amendment At the Cingulate Inc. 2026 Annual Meeting of Stockholders held on July 9, 2026, the Company’s stockholders approved Amendment No. 3 to the Cingulate Inc. 2021 Omnibus Equity Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by… Filing
  6. Jul 2, 2026LeadershipCingulate Therapeutics LLC, a wholly owned subsidiary of Cingulate Inc., entered into an amendment to the Employment Agreement between Matthew N. Brams, Executive Vice President and Chief Medical Officer, and CTx, effective January 1, 2026. Filing
  7. Jun 16, 2026AnnouncementShared information with investors. Filing
  8. Jun 2, 2026AnnouncementThe Company announced that the FDA has issued a CRL for its New Drug Application for CTx-1301. Filing
  9. May 19, 2026LeadershipThe current Class II directors of the Board of Directors of Cingulate Inc., Jeff Ervin and Jay Roberts, will not seek re-election when their respective terms expire at the Company’s 2026 Annual Meeting of Stockholders in an effort to reduce the size of the Board. Filing
  10. May 14, 2026ResultsReleased financial results. Filing
  11. Apr 2, 2026LeadershipFollowing stockholder approval of the Issuance Proposal (defined below), Zhanpeng “Frederick” Jiang was appointed as a member of the Board of Directors of Cingulate Inc., effective immediately, to serve as a Class I director until the Company’s 2028 Annual Meeting of Stockholders and until his… Filing
  12. Mar 24, 2026AgreementCingulate Inc. entered into an ATM Sales Agreement with A.G.P./Alliance Global Partners, as sales agent, pursuant to which the Company may offer and sell, from time to time through A.G.P., shares of the Company’s common stock, par value $0.0001 per share, for aggregate gross proceeds of up to $100… Filing
  13. Mar 18, 2026AnnouncementOther Items On March 17, 2026 the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for a patent application for its lead asset CTx-1301 (dexmethylphenidate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Filing
  14. Feb 17, 2026LeadershipIn connection with the second and final closing of the private placement, the Company appointed Jeff Hargroves as a member of the Board of Directors of the Company, effective immediately, to serve as a Class I director until the Company’s 2028 Annual Meeting of Stockholders and until his successor… Filing
  15. Feb 6, 2026AnnouncementThe Company completed a portion of the private placement previously announced in our Current Report on Form 8-K, dated January 28, 2026, for gross proceeds of $6.5 million. Filing
  16. Jan 28, 2026AgreementCingulate Inc. entered into a securities purchase agreement with the several purchasers named therein, including certain officers, directors and other affiliates of the Company, for the private placement of: (i) 2,147,471 shares of the Company’s common stock, par value $0.0001 per share, (ii) 973… Filing
  17. Jan 15, 2026AnnouncementCingulate Inc. increased the maximum aggregate offering price of the shares of the Company’s common stock, par value $0.0001 per share issuable under the At The Market Offering Agreement with H.C. Wainwright & Co., LLC, dated January 3, 2023, from $23.54 million to $31.94 million and filed a… Filing
  18. Jan 2, 2026SharesSold new shares outside a public offering. Filing
  19. Dec 15, 2025LeadershipAs previously disclosed on August 14, 2025, the board of directors of Cingulate Inc. placed Shane Schaffer, the Company’s Chief Executive Officer and Chairman of the Board, on administrative leave due to a personal legal matter and appointed John. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Cingulate financials

Famous investors that hold CING

2 of the 50 well-known investors we track reported holding CING in their latest 13F filing. The largest position is Jim Simons's, worth $923K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026186,384$923K0.0%+46%
Ken Griffin · Citadel AdvisorsQ3 2026176,930$876K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Cingulate Inc. (CING) stock

Are CING insiders buying or selling?

In the last 12 months, CING insiders reported 5 open-market purchases worth $657K and no sales. The latest trade was on Feb 13, 2026. See every trade.

What is the short interest in CING?

As of Oct 30, 2026, 1.04M CING shares were sold short, 7.1% of the shares outstanding, up 2.0% from the report before. At the average daily volume of 138,009 shares, buying them all back would take about 7.5 trading days (days to cover). See the history.

Which famous investors hold CING?

2 of the 50 well-known investors we track reported CING in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $923K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.